At A Glance
1
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs.
2
No significant events in the past 90 days.
—
Market Cap
—
Revenue
—
Net Income
Employees19
Fundamentals
How The Business Makes Money
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
Industry Biotechnology
Activity
What Changed Recently
No significant events in the past 90 days.
Analyst View
Company Profile
CIKUNKNOWN_RVXCF
ISINCA76128M1086
Phone403-254-9252
Address4820 Richard Road SW, Calgary, AB, T3E 6L1, CA
SEC EDGAR